Raxibacumab

Raxibacumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target Protective antigen of anthrax toxin
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 565451-13-0 N
ATC code None
Chemical data
Formula C6320H9794N1702O1998S42 
Mol. mass 142.93 kDa
 N(what is this?)  (verify)

Raxibacumab [1] is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proved in rabbits and monkeys.[2] As of January 2011, the drug has reached stage three clinical testing in humans.[3]

References

  1. ^ Mazumdar, Sohini (2009). "Raxibacumab". MAbs 1 (6): 531–538. doi:10.4161/mabs.1.6.10195. PMC 2791309. PMID 20068396. http://www.landesbioscience.com/journals/17/article/10195/. 
  2. ^ Migone, TS; Subramanian, GM; Zhong, J; Healey, LM; Corey, A; Devalaraja, M; Lo, L; Ullrich, S et al. (2009). "Raxibacumab for the treatment of inhalational anthrax". The New England journal of medicine 361 (2): 135–44. doi:10.1056/NEJMoa0810603. PMID 19587338. 
  3. ^ ClinicalTrials.gov
Fungal ("-fung-")
Human ("-fungu-")
Viral ("-vi(r)-")
Human ("-viru-")
Humanized ("-vizu-")
Bacterial ("-ba(c)-")
Human ("-bacu-")
Nebacumab • Panobacumab • Raxibacumab
Mouse ("-baco-")
Chimeric ("-baxi-")
Humanized ("-bazu-")
Toxin ("-tox(a)-")
Humanized ("-toxazu-")